Clinical Trial Update: A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006) [Phase 2]

View source ↗

Summary

A Phase IIA study of MK0457 (VX-680) in non-small cell lung cancer has been terminated. The sponsor is Merck Sharp & Dohme LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MK0457 (VX-680)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: TERMINATED